2025
Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
Milrod C, Chorzalska A, Morgan J, Pardo M, Raker C, Ollila T, Pelcovits A, McMahon J, Donnelly S, Carmody C, Dallesandro F, Matasar M, Huntington S, Dubielecka P, Olszewski A. Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2025, 43: 7063-7063. DOI: 10.1200/jco.2025.43.16_suppl.7063.Peer-Reviewed Original ResearchMarginal zone lymphomaCTLA-4 levelsComplete responseT cell activationCTLA-4T cellsImmune biomarkersNK cellsCytokine levelsInvestigator-initiated phase 2 trialMarkers of T-cell activationEffector memory T-cell subsetsIndolent B-cell lymphomaCD8+ T cellsMemory T cell subsetsInvestigation of combination therapyFlow cytometryCD8+ subsetsBaseline cytokine levelsCirculating NK cellsB-cell lymphomaT cell subsetsImmune cell subsetsMultiplex Luminex assaySystemic immune changesSoil‐Transmitted Helminths and the Intricacies of Immunoregulation: Evidence From Amazonian Ecuador for the Importance of Considering Species‐Specific Effects Within the Old Friends Hypothesis
Cepon‐Robins T, Gildner T, Urlacher S, Liebert M, Madimenos F, Bribiescas R, Eick G, Harrington C, Sugiyama L, Snodgrass J. Soil‐Transmitted Helminths and the Intricacies of Immunoregulation: Evidence From Amazonian Ecuador for the Importance of Considering Species‐Specific Effects Within the Old Friends Hypothesis. American Journal Of Human Biology 2025, 37: e70076. PMID: 40444920, PMCID: PMC12175971, DOI: 10.1002/ajhb.70076.Peer-Reviewed Original ResearchConceptsSystemic inflammationImmune biomarkersIL-6Infection statusSpecies-specific relationshipsOld Friends hypothesesSpecies-specific effectsExacerbated systemic inflammationSoil-Transmitted HelminthsFinger-prick blood samplesLevels of CRPLow CRP levelsHelminth speciesCoinfected participantsAmazonian EcuadorHigh IgECRP levelsUninfected participants
2023
Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology
Mortlock R, Ma E, Cohen J, Damsky W. Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. Journal Of Investigative Dermatology 2023, 143: 1412-1422. PMID: 37341663, PMCID: PMC10830170, DOI: 10.1016/j.jid.2023.04.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAtopic dermatitisSkin diseasesInflammatory skin diseaseInflammatory skin conditionImmunologic biomarkersImmune biomarkersPersonalized medicineInflammatory dermatosesImmunologic approachesTherapy selectionSkin conditionsSingle-cell RNA sequencingMolecular profilingBiomarkersTissue stainingPsoriasisDermatitisDiseaseDermatologyRNA sequencingMedicineCurettageDermatosesTherapyPersonalized classificationInflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia
Chen W, Gou M, Wang L, Li N, Li W, Tong J, Zhou Y, Xie T, Yu T, Feng W, Li Y, Chen S, Tian B, Tan S, Wang Z, Pan S, Luo X, Zhang P, Huang J, Tian L, Li C, Tan Y. Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia. European Neuropsychopharmacology 2023, 72: 18-29. PMID: 37058967, DOI: 10.1016/j.euroneuro.2023.03.014.Peer-Reviewed Original ResearchConceptsAnti-inflammatory cytokinesInflammatory disequilibriumImmune-inflammatory response systemPlasma cytokine levelsTreatment-resistant schizophreniaLateral ventricular enlargementLarger lateral ventricle volumesPro-inflammatory cytokinesLateral ventricle volumeNegative Syndrome ScalePotential pathophysiological processesEnzyme-linked immunosorbentHigher PANSS scoresImmune imbalanceCytokine levelsT helperInflammatory imbalanceImmune biomarkersVentricular enlargementClinical manifestationsRegulatory cytokinesHealthy controlsPANSS scoresTh-17Subcortical volumesNonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19
Cohen A, Glick L, Lee S, Kunitomo Y, Tsang D, Pitafi S, Toro P, Ristic N, Zhang E, Carey G, Datta R, Dela Cruz C, Gautam S. Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19. European Clinical Respiratory Journal 2023, 10: 2174640. PMID: 36815942, PMCID: PMC9930745, DOI: 10.1080/20018525.2023.2174640.Peer-Reviewed Original ResearchSevere COVID-19Bacterial superinfectionBacterial pneumoniaCOVID-19Lower respiratory culturesSuperimposed bacterial pneumoniaUtility of procalcitoninProcalcitonin measurementImmune biomarkersClinical resemblanceRespiratory culturesImmunomodulatory agentsProcalcitoninPatientsBacterial infectionsSuperinfectionCurve analysisSignificant riskCharacteristic curvePneumoniaTime of cultureDiagnosisInfectionBiomarkers
2022
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Journal For ImmunoTherapy Of Cancer 2022, 10: e005119. PMID: 36252998, PMCID: PMC9577940, DOI: 10.1136/jitc-2022-005119.Peer-Reviewed Original ResearchConceptsObjective response rateProgression-free survivalMetastatic breast cancerAdverse eventsBreast cancerT-DM1Immune biomarkersTrastuzumab emtansineHER2-positive metastatic breast cancerMetastatic HER2-positive breast cancerGrade 3 adverse eventsMedian progression-free survivalTreatment-related adverse eventsHuman epidermal growth factor receptor 2Cell death ligand 1HER2-positive breast cancerEpidermal growth factor receptor 2Dose-finding cohortPhase 2 dosePhase Ib studyPhase Ib trialAnti-HER2 therapyDose-limiting toxicityGrowth factor receptor 2Immune checkpoint blockade
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatientsAtezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal Of The National Cancer Institute 2021, 113: 1005-1016. PMID: 33523233, PMCID: PMC8328980, DOI: 10.1093/jnci/djab004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerMetastatic triple-negative breast cancerProgression-free survivalPD-L1Tumor immune microenvironmentBreast cancerIntratumoral CD8Nab-paclitaxelClinical benefitImmune microenvironmentImmune cellsBRCA1/2 mutationsAdvanced triple-negative breast cancerStromal tumor-infiltrating lymphocytesNab-paclitaxel 100Immune checkpoint inhibitorsOverall survival benefitTumor-infiltrating lymphocytesMetastatic tumor tissueBRCA1/2 mutation statusCheckpoint inhibitorsOverall survivalSurvival benefitImmune biomarkersClinical activityTriple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHuman epidermal growth factor receptor 2Vascular endothelial growth factorHomologous recombination deficiencyBreast cancerEpidermal growth factor receptorGrowth factor receptorPredictive biomarkersTreatment optionsFibroblast growth factor receptorManagement of TNBCEpidermal growth factor receptor 2Factor receptorGrowth factor receptor 2PI3K/Akt/mTORLimited treatment optionsNTRK gene fusionsFactor receptor 2Akt/mTOREndothelial growth factorCell-free DNAAntibody-drug conjugatesClinical outcomesImmune biomarkersPoor prognosis
2019
Manganese is associated with increased plasma interleukin-1β during pregnancy, within a mixtures analysis framework of urinary trace metals
Aung M, Meeker J, Boss J, Bakulski K, Mukherjee B, Cantonwine D, McElrath T, Ferguson K. Manganese is associated with increased plasma interleukin-1β during pregnancy, within a mixtures analysis framework of urinary trace metals. Reproductive Toxicology 2019, 93: 43-53. PMID: 31881266, PMCID: PMC7138746, DOI: 10.1016/j.reprotox.2019.12.004.Peer-Reviewed Original ResearchConceptsIL-1BBayesian kernel machine regressionKernel machine regressionInterleukin-1bInterquartile range differenceCross-sectional studyAssociated with biomarkersReproductive health outcomesImmune signaling moleculesHealth outcomesLIFECODES birth cohortPregnant womenImmune perturbationsImmune biomarkersBirth cohortUrinary manganeseMachine regressionLinear regressionExposure analytesAssociationSignaling moleculesRegressionPair-wise associationsTrimesterPregnancyPrediction and associations of preterm birth and its subtypes with eicosanoid enzymatic pathways and inflammatory markers
Aung M, Yu Y, Ferguson K, Cantonwine D, Zeng L, McElrath T, Pennathur S, Mukherjee B, Meeker J. Prediction and associations of preterm birth and its subtypes with eicosanoid enzymatic pathways and inflammatory markers. Scientific Reports 2019, 9: 17049. PMID: 31745121, PMCID: PMC6863859, DOI: 10.1038/s41598-019-53448-z.Peer-Reviewed Original ResearchConceptsSpontaneous preterm birthPreterm birthMultiple logistic regressionCross-sectional study of pregnant womenAssociation of preterm birthCases of preterm birthStudy of pregnant womenOverall preterm birthPreterm birth casesPreterm birth outcomesCytochrome P450 metabolitesLogistic regressionOxidative stress markersAberrant placentationCross-sectional studyDelivered termCytochrome P450 productPredictive biomarkersPregnant womenPretermEicosanoid metabolitesImmune biomarkersLipoxygenase metabolitesBirth casesResolvin D1
2018
The Relationships between Maternal Urinary Trace Metals and Plasma Immune Biomarkers during Pregnancy
Aung T, Meeker J, Boss J, Bakulski K, Mukherjee B, Cantonwine D, McElrath T, Ferguson K. The Relationships between Maternal Urinary Trace Metals and Plasma Immune Biomarkers during Pregnancy. ISEE Conference Abstracts 2018, 2018 DOI: 10.1289/isesisee.2018.o01.04.23.Peer-Reviewed Original Research
2017
Host-related immunodeficiency in the development of multiple myeloma
Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leukemia & Lymphoma 2017, 59: 1127-1132. PMID: 28792255, PMCID: PMC6750254, DOI: 10.1080/10428194.2017.1361026.Peer-Reviewed Original ResearchConceptsMultiple myelomaLymphocyte subsetsCD57- subsetImmune biomarkersDevelopment of MMMyeloma precursor diseaseNK cell proportionNovel immune biomarkersProgression of SMMMultiparametric flow cytometrySMM patientsImmune changesImmune patternsClinical guidancePrecursor diseaseCell proportionFlow cytometryMGUSPotential markerImmunodeficiencySequential changesMyelomaPatientsPrecursor conditionsProgressionSignificance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
Dosani T, Covut F, Beck R, Driscoll J, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal 2017, 7: e579-e579. PMID: 28665418, PMCID: PMC5520407, DOI: 10.1038/bcj.2017.60.Peer-Reviewed Original ResearchImmune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).
Waks A, Barry W, Gjini E, Dillon D, Rodig S, Brock J, Baltay M, Savoie J, Stover D, Winer E, Krop I, Tolaney S. Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev). Journal Of Clinical Oncology 2017, 35: e12134-e12134. DOI: 10.1200/jco.2017.35.15_suppl.e12134.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesTPD-L1Miller-PaynePathologic responseImmune biomarkersHormone receptor-positive breast cancer patientsReceptor-positive breast cancer patientsPanCancer Immune Profiling PanelResidual cancer burden scorePathologic complete responsePD-L1 expressionBreast cancer patientsPD-L1 scoresImmune Profiling PanelImportant clinical implicationsPreoperative chemotherapyComplete responseProspective trialTumor-immune interactionsBurden scoreCancer patientsImmune microenvironmentUnadjusted analysesTumor gradeTreatment outcomes
2016
Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans
Basa R, Davies V, Li X, Murali B, Shah J, Yang B, Li S, Khan M, Tian M, Tejada R, Hassan A, Washington A, Mukherjee B, Carethers J, McGuire K. Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans. PLOS ONE 2016, 11: e0156660. PMID: 27310868, PMCID: PMC4911070, DOI: 10.1371/journal.pone.0156660.Peer-Reviewed Original ResearchConceptsGranzyme B+ cellsColorectal cancerCytotoxic immunityB+ cellsAnti-tumor cytotoxic T lymphocytesColon cancerMicrosatellite-stable colon cancerCytotoxic T lymphocytesIL-17 expressionWilcoxon rank sum testProtection to patientsAfrican American colorectal cancerRank sum testTwo-sample Wilcoxon rank-sum testCD57+CD8+Invasive borderCytotoxic markersNo significant differenceT lymphocytesColon tumorsDescriptive summary statisticsImmune biomarkersTumor samplesImmune cytotoxicity
2015
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake C, O'Hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal For ImmunoTherapy Of Cancer 2015, 3: p83. PMCID: PMC4645499, DOI: 10.1186/2051-1426-3-s2-p83.Peer-Reviewed Original Research
2013
Immune gene expression in primary melanomas to predict lower risk of recurrence and death.
Sivendran S, Chang R, Harcharik S, Hall L, Bernardo S, Moskalenko M, Phelps R, Sivendran M, Cohain A, DiFeo A, Parides M, Lebwohl M, Friedlander P, Banchereau J, Bhardwaj N, Oh W, Burakoff S, Palucka K, Merad M, Saenger Y. Immune gene expression in primary melanomas to predict lower risk of recurrence and death. Journal Of Clinical Oncology 2013, 31: 3014-3014. DOI: 10.1200/jco.2013.31.15_suppl.3014.Peer-Reviewed Original ResearchPrediction of non-recurrenceIndependent patient cohortReceiver Operating CharacteristicProlonged survivalMRNA copy numberNon-recurrenceTraining cohortPatient cohortGene panelLow risk of recurrencePrimary human melanomaStandard prognostic indicatorsImmune-related genesRisk of recurrenceReceiver operating characteristic curvePrimary melanomaImmunotherapy studiesMelanoma recurrencePrognostic indicatorImmune biomarkersRecurrence riskMitotic rateHuman melanomaPrevent recurrencePatient stratification
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply